Valuation : Biotika

Market Cap 12.04M 14.03M 11.27M 10.32M 19.44M 1.34B 19.5M 133M 52.18M 675M 52.66M 51.52M 2.23B P/E 2024
-4.39x
P/E 2025 -5.89x
Enterprise Value 8.33M 9.7M 7.79M 7.14M 13.45M 926M 13.48M 92.3M 36.08M 467M 36.41M 35.63M 1.55B EV / Sales 2024
0.55x
EV / Sales 2025 0.18x
Free-Float
42.84%
Yield 2024 *
-
Yield 2025 -
1 day+1.18%
1 week+1.18%
Current month-14.00%
1 month-15.69%
3 months+62.26%
6 months+56.36%
Current year+72.00%
1 week 17.2
Extreme 17.2
17.2
1 month 17
Extreme 17
20
Current year 9
Extreme 9
23
1 year 7
Extreme 7
23
3 years 7
Extreme 7
25
5 years 7
Extreme 7
42
10 years 7
Extreme 7
50.02
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - -
Chief Investment Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%+1.18%+115.00%-21.82% 14.03M
+0.73%+0.70%+19.56%+71.29% 47.78B
+0.33%+1.37%+54.82%+122.59% 40.3B
+3.41%+7.67%+20.38%+87.48% 12.03B
+1.23%-0.14%-10.12%+15.55% 11.88B
+0.19%0.00%+30.98%+150.00% 9.24B
+0.45%+3.73%+25.09%+46.01% 7.83B
-0.04%-0.20%+52.20%-12.02% 7.34B
+0.89%+9.50%+26.11%+220.67% 7.21B
+0.95%-8.22%-39.88%+16.67% 5.28B
Average +0.93%-0.36%+29.42%+69.64% 14.89B
Weighted average by Cap. +0.81%+1.06%+27.63%+86.77%

Financials

2024 2025
Net sales 17.24M 20.08M 16.14M 14.78M 27.84M 1.92B 27.92M 191M 74.71M 967M 75.4M 73.77M 3.2B 18.15M 21.15M 17M 15.56M 29.32M 2.02B 29.4M 201M 78.67M 1.02B 79.4M 77.68M 3.37B
Net income -2.39M -2.78M -2.24M -2.05M -3.86M -266M -3.87M -26.5M -10.36M -134M -10.45M -10.23M -444M -1.19M -1.39M -1.11M -1.02M -1.92M -132M -1.93M -13.18M -5.15M -66.67M -5.2M -5.09M -221M
Net Debt -1.07M -1.24M -997K -913K -1.72M -118M -1.72M -11.81M -4.62M -59.72M -4.66M -4.56M -198M -3.71M -4.33M -3.48M -3.18M -6M -413M -6.02M -41.18M -16.1M -208M -16.25M -15.9M -689M
Logo Biotika
Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.
Employees
165
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. 1BSL01AE Stock